About Anavex Life Sciences Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.anavex.com
Frequently Asked Questions
What is the 52-week range for AVXL?
The 52-week high is $10.38 and the 52-week low is $1.88.
What is the P/E ratio for AVXL?
The P/E ratio data is currently unavailable.
What is the dividend yield for AVXL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -11.43%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.06.
Analyst Recommendation Trends
Wall Street analyst consensus for AVXL over the last few months:
Latest AVXL News
Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees –
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders –CENTENNIAL, Colo., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex” or the “Company”), announced its plan following its anticipated success in the Company’s upcoming proxy vote. PVG management is optimistic that its slate of highly
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change
-- Proxy advisor recommends voting “FOR” two of PVG’s director nominees and “AGAINST” two incumbent director nominees including the board’s current chair on the GOLD Universal Proxy Card – -- PVG encourages stockholders to vote to elect all six of its director nominees by voting the GOLD Universal Proxy Card to help the Company realize the full potential of its valuable assets -- CENTENNIAL, Colo., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 sh
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround September 16, 2026 10:00...
PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board’s nominees – -- It’s too little, too late after a few months of the incumbent board’s half-measures, so stockholders are encouraged to vote the GOLD Universal Proxy Card to elect PVG’s six nominees to help Anavex realize the full potential of its valuable assets while there’s still time -- CENTENNIAL, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PVG Asset Managem
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that leading independent proxy advisory firm Institutional
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
CENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ: AVXL) ("Anavex" or the "Company"), today announced that it will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors at the upcoming 2026 Annual Meeting of Stockholders. During the call, PVG will discuss its views regarding the Company's recent performance, corporate governance, capital markets strategy, lea
Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript
Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications September 9, 2026 4:00 PM EDTCompany...
PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)
Why the Anavex Board should be replaced and a New CEO hiredCENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (Nasdaq: AVXL "Anavex" or the "Company"), believes the Anavex Board of Directors should be replaced and an experienced CEO should be hired. The “rookie” CEO held five positions across four organizations in seven years, none held longer than about 27 months.(1) On 27 February 2026, during her tenure as Aard
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities. Anavex Invest
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
CENTENNIAL, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of Anavex Life Sciences Corp. (“Anavex” or the “Company”), today sent an open letter to the stockholders of Anavex.In its letter, PVG details why it is calling for change at Anavex. PVG notes that the Company’s Board of Directors (the “Board”) has demonstrated a pattern of operational and corporate governance failures, a lack of accountability, and a failure to deliver meaningful shareholder v
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Boenisch Sandra | +25,000 | - | - |
| 2026-09-24 | Boenisch Sandra | +25,000 | - | - |
| 2026-09-24 | Boenisch Sandra | +25,000 | - | - |
| 2026-09-24 | Boenisch Sandra | +20,000 | - | - |
| 2026-01-06 | Boenisch Sandra | +12,500 | - | - |
| 2026-01-06 | MISSLING CHRISTOPHER U | +125,000 | - | - |